Early Angiotensin II in the Emergency Department

Recruiting now · Phase 4

Conditions studied: Septic Shock

In brief

This pilot study will enroll 20 patients with septic shock and require emergent vasopressor support in the emergency department (ED). The primary objective of the study is to determine the feasibility of early peripheral administration of angiotensin II for treatment of septic shock in the ED

Key facts

Study ID

NCT06693726

Run by

Brett A Faine

People needed

20

Starts

2025-04-01

Expected to finish

2026-11-30

Last updated by the study team

2026-03-11

Who can join

Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥18; and
• Requiring norepinephrine at a dose of 0.05-0.25 mcg/kg/min mcg/kg/minute despite adequate fluid resuscitation; and
• Receiving intravenous antibiotics or clinician's intention to administer antibiotics at the time of enrollment; and
• Can provide written informed consent (or legally authorized representative).

You may not qualify if…

• Acute coronary syndrome;
• Cardiogenic shock;
• Patients with a history of mesenteric ischemia;
• Patients with a history of having an aortic dissection or abdominal aortic aneurysm;
• Patients with an expected lifespan of <12 hours;
• Patients with hemorrhagic shock (e.g., actively receiving transfusion of packed red blood cells);
• Active administration of two vasoactive agents before enrollment; and
• Pre-existing thromboembolic disease or inability to tolerate pharmacologic VTE prophylaxis.

Where it is running

• University of Iowa Hospitals and Clinics — Iowa City, Iowa, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.